Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis.

Medicine (Baltimore) · 2018 · PMC6283083 · PMID 30508972

Europe PMC DOI

hedged sentence

0.4600

closest p · 9.2× alpha

0.4600

boldest claim

The sentences

a nonsignificant trendP = .46not close (p > 0.1)

A nonsignificant trend towards all-cause death (RR: 0.38; 95% CI: 0.03–4.92; P = .46) or major bleeding (RR: 1.59; 95% CI: 0.77–3.27; P = .21) risk between rivaroxaban and enoxaparin prophylaxis was found.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.